Prof Nicolas Penel, MD, PhD is currently Director of Clinical Research and Innovation Department and Head of the General Oncology Department the Medical Oncology Department at the Oscar Lambret Cancer Center in Lille, North of France. In 1999, Dr Penel received his medical degree in medicine from the University of Lille and was awarded his PhD in 2008 (Methodology in clinical research). He continued his training in oncology at various institutions, including Harvard University and EORTC Headquarters. He is also Professor of Medical Oncology at Lille University, Lille, North of France.
His main interests are clinical management of rare cancers, especially sarcomas and cancers of unknown primary site and methodology of early phase clinical trials. He is coordinator of numerous clinical trials assessing new drugs in rare cancers and urological cancers. Prof Penel is a member of the American Society of Clinical Oncology, the European Society for Medical Oncology and the French Society of Cancer.
Prof Penel is the author or co-author of over 240 publications in medical oncology.
Most recent issued publications include
Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group. Penel N, Le Cesne A, Bonvalot S, Giraud A, Bompas E, Rios M, Salas S, Isambert N, Boudou-Rouquette P, Honore C, Italiano A, Ray-Coquard I, Piperno-Neumann S, Gouin F, Bertucci F, Ryckewaert T, Kurtz JE, Ducimetiere F, Coindre JM, Blay JY. Eur J Cancer. 2017 Jul 20;83:125-131.
REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis. Berry V, Basson L, Bogart E, Mir O, Blay JY, Italiano A, Bertucci F, Chevreau C, Clisant-Delaine S, Liegl-Antzager B, Tresch-Bruneel E, Wallet J, Taieb S, Decoupigny E, Le Cesne A, Brodowicz T, Penel N. Cancer. 2017 Jun 15;123(12):2294-2302
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO). Lebellec L, Bertucci F, Tresch-Bruneel E, Bompas E, Toiron Y, Camoin L, Mir O, Laurence V, Clisant S, Decoupigny E, Blay JY, Goncalves A, Penel N. Oncotarget. 2016 Nov 8;7(45):73984-73994